Ultragenyx to Participate in Investor Conferences in September
29 août 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 Cantor Global Healthcare Conference on September 17 Bank of America Global Healthcare Conference on September 18 NOVATO,...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 août 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
01 août 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million ...
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
25 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
24 juil. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
17 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 juin 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2024 20h49 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12 juin 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...